RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
164 hedge funds and large institutions have $1.46B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 65 increasing their positions, 39 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
12% less capital invested
Capital invested by funds: $1.66B → $1.46B (-$200M)
61% less call options, than puts
Call options by funds: $21.3M | Put options by funds: $54.7M
Holders
164
Holding in Top 10
5
Calls
$21.3M
Puts
$54.7M
Top Buyers
| 1 | +$29.2M | |
| 2 | +$13.9M | |
| 3 | +$12.9M | |
| 4 |
SPC
Slate Path Capital
New York
|
+$9.63M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$9.55M |
Top Sellers
| 1 | -$49.6M | |
| 2 | -$18.5M | |
| 3 | -$8.39M | |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$7.44M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$5.01M |